Scope
The EULAR 2023 update organizes systemic-sclerosis treatment by affected organ rather than offering one regimen for every patient. It expands options for skin fibrosis and interstitial lung disease, supports combination treatment for pulmonary arterial hypertension, and retains targeted approaches to vascular, renal and gastrointestinal complications.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Choose treatment for the organ pattern
- Consider disease duration, comorbidities, patient preferences, drug availability and cost when selecting systemic-sclerosis therapy. The authors explicitly reject a uniform strategy; their graphical algorithms are summaries that need interpretation alongside the full recommendations. [1]
Raynaud phenomenon and digital ulcers
- Use a dihydropyridine calcium-channel blocker, usually oral nifedipine, as first-line treatment for systemic-sclerosis Raynaud phenomenon. PDE5 inhibitors should also be considered for this manifestation. [1]
- For severe systemic-sclerosis Raynaud phenomenon that has not responded to oral treatment, consider intravenous iloprost as a subsequent option. This escalation is tied to severe disease and oral-treatment failure. [1]
- For systemic-sclerosis digital ulcers, consider PDE5 inhibitors and/or intravenous iloprost. This is an ulcer-treatment recommendation, distinct from prevention of new ulcers. [1]
- Consider bosentan to reduce new digital ulcers. The recommendation is specific to bosentan rather than the whole endothelin-receptor-antagonist class, because trials of macitentan did not show the same benefit. [1]
- The update makes no recommendation for or against fluoxetine for Raynaud phenomenon because it was deprioritized and not included in the updated literature review. Absence of a recommendation is not proof of ineffectiveness. [1]
Treat systemic-sclerosis pulmonary arterial hypertension
- Consider a PDE5 inhibitor together with an endothelin receptor antagonist as first-line treatment for systemic-sclerosis pulmonary arterial hypertension. The discussion supports initiating combination treatment at diagnosis of PAH. [1]
- For advanced systemic-sclerosis PAH in functional classes III or IV, consider intravenous epoprostenol. Other prostacyclin analogues or agonists should also be considered for SSc-PAH according to the selected treatment strategy. [1]
- Riociguat can be considered for systemic-sclerosis PAH. This recommendation identifies an option; the summary does not establish a safe combination regimen with other PAH drugs. [1]
- Do not use anticoagulants such as warfarin specifically to treat systemic-sclerosis PAH. This negative recommendation addresses the PAH indication; it is not a statement about separate indications for anticoagulation. [1]
Act promptly in renal crisis
- Start an ACE inhibitor immediately when scleroderma renal crisis is diagnosed. The task force did not extend this treatment recommendation into a preventive recommendation, so it should not be read as routine prophylaxis against renal crisis. [1]
- When glucocorticoid treatment is necessary in systemic sclerosis, monitor blood pressure regularly to detect renal crisis. The recommendation is a monitoring requirement, not evidence that glucocorticoids prevent this complication. [1]
Match gastrointestinal treatment to the manifestation
- Consider proton-pump inhibition for systemic-sclerosis gastro-oesophageal reflux and prevention of oesophageal ulceration or strictures. The discussion notes incomplete symptom control in some patients and limited evidence about long-term safety in this population. [1]
- Consider prokinetic medicines for symptomatic systemic-sclerosis-related motility disturbance. This recommendation is symptom-directed and does not imply that one prokinetic is suitable for all gastrointestinal manifestations. [1]
- Consider rotating antibiotics for small-intestinal bacterial overgrowth. The paper recognizes sparse gastrointestinal evidence and the need for further studies; this summary does not provide an antibiotic rotation or diagnostic testing protocol. [1]
Skin and interstitial lung disease
- For systemic-sclerosis skin fibrosis, consider methotrexate, mycophenolate mofetil and/or rituximab. These organ-specific options are not interchangeable with every treatment recommended for associated lung disease. [1]
- Tocilizumab may be considered for skin fibrosis in early inflammatory dcSSc. The trial findings discussed do not support it as first-line skin treatment; preserve that population and limited positioning when considering it. [1]
- For systemic-sclerosis interstitial lung disease, consider mycophenolate mofetil, cyclophosphamide or rituximab. Trial discussion reports better tolerability with mycophenolate than cyclophosphamide, and does not establish a definitive oral-versus-IV cyclophosphamide risk–benefit comparison. [1]
- Consider nintedanib alone or with mycophenolate for SSc-associated interstitial lung disease. Tocilizumab should also be considered for SSc-ILD; its evidence discussed here comes from trials in early inflammatory disease without background treatment, with lung outcomes secondary to the skin endpoint. [1]
Selected severe disease and musculoskeletal involvement
- High-intensity immunosuppression followed by autologous stem-cell transplantation may be considered for selected patients with early dcSSc and poor prognosis, without advanced cardiorespiratory involvement. Treatment-related mortality, particularly with suboptimal cardiac function, requires careful consideration. [1]
- Consider methotrexate for systemic-sclerosis musculoskeletal involvement. The update notes insufficient good-quality evidence for corticosteroids, tocilizumab or rituximab on joint involvement; it does not convert exploratory treatments into established joint recommendations. [1]
Limitations and use
- This is an organ-directed treatment summary, not a complete diagnostic, screening, dosing, contraindication or monitoring protocol. Treatment recommendations for pulmonary arterial hypertension must not be extrapolated to every cause of pulmonary hypertension. The article labels recommendations by evidence grade; options and combinations still require specialist selection and patient-specific safety assessment.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Systemic sclerosis — 2023 update
Guideline recommendation text consulted
Publication details
- Issuing organisation
- EULAR
- First published
- 10 October 2024
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.